H Mo

Summary

Affiliation: Gilead Sciences
Country: USA

Publications

  1. doi request reprint Antiviral response and resistance analysis of treatment-naïve HCV infected patients receiving multiple doses of the NS3 protease inhibitor GS-9256
    Hongmei Mo
    Gilead Sciences Inc, Foster City, CA, USA Electronic address
    Antiviral Res . 2017
  2. doi request reprint Estimation of inhibitory quotient using a comparative equilibrium dialysis assay for prediction of viral response to hepatitis C virus inhibitors
    H Mo
    Department of Clinical Virology, Gilead Sciences Inc, Foster City, CA, USA
    J Viral Hepat 18:338-48. 2011
  3. doi request reprint Natural variation in drug susceptibility to HCV polymerase inhibitors in treatment-naïve HCV patient isolates
    S C C Sun
    Department of Clinical Virology, Gilead Sciences, Inc, Foster City, CA 94404, USA
    J Viral Hepat 18:861-70. 2011
  4. doi request reprint Antiviral response and resistance analysis of treatment-naïve HCV-infected patients receiving single and multiple doses of GS-9190
    H Mo
    Gilead Sciences Inc, Foster City, CA, USA
    J Viral Hepat 23:644-51. 2016

Collaborators

Detail Information

Publications4

  1. doi request reprint Antiviral response and resistance analysis of treatment-naïve HCV infected patients receiving multiple doses of the NS3 protease inhibitor GS-9256
    Hongmei Mo
    Gilead Sciences Inc, Foster City, CA, USA Electronic address
    Antiviral Res . 2017
    ..The R155, A156 and D168 substitutions identified in patients confer reduced susceptibility to GS-9256 and other PIs in vitro...
  2. doi request reprint Estimation of inhibitory quotient using a comparative equilibrium dialysis assay for prediction of viral response to hepatitis C virus inhibitors
    H Mo
    Department of Clinical Virology, Gilead Sciences Inc, Foster City, CA, USA
    J Viral Hepat 18:338-48. 2011
    ..This method provides a framework for the evaluation of other classes of drugs that are bound by serum proteins but require the presence of serum for in vitro evaluation...
  3. doi request reprint Natural variation in drug susceptibility to HCV polymerase inhibitors in treatment-naïve HCV patient isolates
    S C C Sun
    Department of Clinical Virology, Gilead Sciences, Inc, Foster City, CA 94404, USA
    J Viral Hepat 18:861-70. 2011
    ..In addition, the lack of correlation among the susceptibilities to three classes of HCV polymerase inhibitors evaluated here supports their possible combined use in a combination therapy strategy...
  4. doi request reprint Antiviral response and resistance analysis of treatment-naïve HCV-infected patients receiving single and multiple doses of GS-9190
    H Mo
    Gilead Sciences Inc, Foster City, CA, USA
    J Viral Hepat 23:644-51. 2016
    ..Y448H confers reduced susceptibility to GS-9190 and other NNIs and persisted in most patients for months post-treatment. ..